CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform ...
Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development ...
Cross-species research shows that RNA splicing patterns, not just gene activity, track maximum lifespan in mammals, revealing a new axis of longevity control.
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...
New research shows how muscular dystrophy (DM1) damages the heart over time, stressing the need for early diagnosis and ...
Myotonic dystrophy type 1 (DM1) is the most common cause of adult-onset muscular dystrophy, a genetic disorder that leads to ...
Paving way for new therapies, researchers decode how parasites that spread one of the world's deadliest diseases use trickery ...
Morning Overview on MSN
Study: RNA drugs work best when they reshape RNA, not just bind to it
Researchers led by Davide Incarnato at the University of Groningen have demonstrated that the FDA-approved cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results